Skip To Main Content

Určeno pro odbornou veřejnost

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

חיסון למניעת RSV

Číst více

Tọa Đàm Trực Tuyến Cập Nhật Các Tiến Bộ Trong Phẫu Thuật Thẩm Mỹ & Chấn Thương Chỉnh Hình - Vai Trò Của Alphachymotrypsine Trên Lâm Sàng

Číst více

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více

The Impact of Exacerbations in COPD

Číst více

Role of type 2 Inflammation

Číst více

Quality of life and symptom measurement in COPD Patients

Číst více

One minute to ignite new thinking in COPD

Understanding type 2 inflammation^* may help shed light on why some patients continue to exacerbate. Watch this video to learn how.¹

Číst více

Videotallenne: Beyfortus^® -valmisteen oikea ja turvallinen käyttö

Číst více